Sundar Jagannath, MBBS

Sundar Jagannath, MBBS, is Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai and The Tisch Cancer Institute. He is a renowned expert in the research and treatment of multiple myeloma. Dr. Jagannath serves as Network Director for the Center of Excellence for Multiple Myeloma, expanding clinical research across the Mount Sinai Health System and collaborations with other institutions.

Dr. Jagannath led the multiple myeloma program from 2010 until September 2024, growing it into a leading clinical and clinical research service. Prior to joining Mount Sinai, Dr. Jagannath was chief of the multiple myeloma and transplant program at St. Vincent’s Hospital Comprehensive Cancer Center from 1998 until the hospital closed in April 2010.

Throughout his career, Dr. Jagannath has focused on developing clinical trials using novel therapeutics. Under his leadership, participation in pivotal clinical trials s has led to FDA approval of many agents, including Velcade, Lenalidomide, Pomalidomide, Carfilzomib, Daratumumab, Elotuzumab, Selinexor, Cilta-Cel, Ide-Cel and Talquetamab. A survivorship clinic, initiated by Dr. Jagannath, follows long-term patients cured of their myeloma. The goal is to unlock the secret of the success of these patients by studying their bone marrow microenvironment and immune reconstitution.

Dr. Jagannath has published more than 400 peer-reviewed articles in top journals, including the New England Journal of Medicine, Blood, the Journal of Clinical Oncology and Cancer, and authored 28 book chapters. He has received numerous recognitions and awards, including the Innovator Award and Accelerator Award from the Multiple Myeloma Research Consortium and the Waldenström Lifetime Achievement Award from the International Myeloma Society.